Welcome to our dedicated page for Pmv Pharmaceuticals news (Ticker: PMVP), a resource for investors and traders seeking the latest updates and insights on Pmv Pharmaceuticals stock.
PMV Pharmaceuticals, Inc. (PMVP) is a clinical-stage biopharmaceutical company pioneering precision oncology therapies targeting p53 mutations, a key driver in many cancers. This page provides investors and researchers with verified updates on clinical trials, regulatory milestones, and corporate developments.
Access real-time announcements including phase progressions for PC14586 and other pipeline candidates, financial disclosures, and strategic collaborations. Our curated repository ensures you stay informed about PMVP’s tumor-agnostic approach to reactivating p53’s tumor-suppressing function.
Key updates cover clinical data publications, FDA designations, and research partnerships advancing small-molecule therapeutics. Bookmark this page for streamlined access to PMVP’s progress in developing treatments that address unmet needs in genetically defined cancers.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) announced that CEO David H. Mack, Ph.D., will participate in a panel on lung cancer at the 42nd Annual Cowen Health Care Conference from March 7-9, 2022. The panel discussion is scheduled for March 9, 2022, from 9:10 AM to 10:10 AM EST. The company, focused on developing small molecule therapies targeting p53 mutations, aims to connect with institutional investors during the conference.
PMV Pharma was founded to innovate in oncology, leveraging over 40 years of research into p53 biology.
PMV Pharmaceuticals, a precision oncology company, announced that its CEO, David H. Mack, will participate in a Fireside Chat at the Guggenheim Healthcare Talks 2022 Oncology Day on February 9, 2022, at 10:30 am ET. This event will include one-on-one investor meetings, emphasizing PMV's focus on tumor-agnostic therapies targeting p53 mutants. The company is recognized for its groundbreaking work in p53 biology, established by co-founder Dr. Arnold Levine in 1979. For more details, visit PMV Pharma's website.
PMV Pharmaceuticals (Nasdaq: PMVP) announced the appointment of Kirsten Flowers to its Board of Directors, effective January 6, 2022. This change follows the resignation of Peter Thompson, M.D., who contributed to the company's growth and IPO success. Flowers brings extensive experience in oncology product launches and commercial strategy, previously serving as Chief Commercial Officer at Kura Oncology and leading Array Biopharma's first commercial launch. Her expertise is expected to enhance PMV's strategy as it advances its candidate PC14586 targeting p53 mutations.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a leader in precision oncology, announced that David H. Mack, Ph.D., will participate in a "Fireside Chat" at the Evercore ISI 4th Annual HealthCONx Conference from November 30 to December 2, 2021. The chat is scheduled for December 2, 2021, at 11:20 am ET. PMV Pharma specializes in developing small molecule therapies targeting p53 mutations, which are prevalent in about half of all cancers. This event will also include one-on-one investor meetings.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) reported its Q3 2021 financial results, highlighting significant developments in its lead candidate, PC14586, targeting p53 Y220C mutations. With a robust cash position of $326.3 million as of September 30, 2021, PMVP anticipates sufficient funds to support operations through 2023. However, the company recorded a net loss of $39.5 million for the first nine months of 2021, up from $24.0 million in the same period last year, driven by increased R&D and G&A expenses.
PMV Pharmaceuticals (Nasdaq: PMVP) has appointed Tim Smith as Senior Vice President, Head of Corporate Development. Smith brings extensive experience from previous leadership roles in biotechnology, including Verseau Therapeutics and IDEAYA Biosciences. His expertise is expected to enhance PMV's efforts in developing tumor-agnostic therapies targeting p53 mutants, crucial for many cancers. The company's lead candidate, PC14586, aims to reactivate the p53 protein in patients with specific mutations.
PMV Pharmaceuticals (Nasdaq: PMVP) announced that its CEO, David H. Mack, Ph.D., will present at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 4:15 PM ET. The company is known for its innovative work in precision oncology, focusing on small molecule therapies targeting p53 mutants, which are implicated in nearly half of all cancers. PMV Pharma aims to revolutionize cancer treatment through its unique insights into p53 biology, established by co-founder Dr. Arnold Levine in 1979.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) reported its Q2 2021 financial results, ending the quarter with $339.0 million in cash, down from $361.4 million at year-end 2020. The net loss for the six months was $24.5 million, up from $15.2 million in the same period last year. R&D expenses rose to $15.2 million, primarily due to increased clinical costs for the lead drug PC14586. Meanwhile, G&A expenses surged to $9.6 million, reflecting infrastructure costs for public operations. The company continues to enroll patients in its Phase 1/2 trial for PC14586, which targets p53 mutants in advanced solid tumors.
PMV Pharmaceuticals (Nasdaq: PMVP) announced its participation in the Bank of America Securities 2021 Napa Biopharma Virtual Conference, where David H. Mack, Ph.D., President & CEO, will present on June 14, 2021, at 2:30 PM ET. The company specializes in developing tumor-agnostic therapies targeting p53 mutations, prevalent in nearly half of all cancers. PMV Pharma combines over 40 years of p53 biology expertise with a strong pharmaceutical development focus. For more information, visit pmvpharma.com.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) announced that its CEO, David H. Mack, will present at the Goldman Sachs Annual Global Healthcare Conference on June 9, 2021, at 5:30 PM ET. The company, focused on developing small molecule, tumor-agnostic therapies targeting p53 mutants, invites investors to participate in one-on-one meetings during the event. Further details, including a link to the webcast, are provided in the release. PMV Pharma is headquartered in Cranbury, New Jersey, and utilizes over four decades of p53 biology research to advance its therapies.
FAQ
What is the current stock price of Pmv Pharmaceuticals (PMVP)?
What is the market cap of Pmv Pharmaceuticals (PMVP)?
